Last spring, when it was heard that Donald Trump had offered CureVac of Tübingen, Germany a €1 billion offer for the production of a coronavirus vaccine specifically produced for the US market, the situation raged. This indecent proposal was rejected, and CureVac remains Europe’s greatest hope, especially when it cooperates with the pharmaceutical giant Bayer, the company will mass-produce vaccines, it wrote. German wave.
It turns out that hope is futile. Not only have several manufacturers made vaccines before this company, but data now shows that the efficiency of the CureVacom vaccine, which is still in the testing stage, is only 47%, which is not enough to obtain a license. According to reports, the first cross-section shows that the efficacy of the vaccine depends on the age of the person and the variant of the coronavirus.
These are only interim results, but the value of the company’s shares in Tübingen on Wall Street immediately fell by half.
The CureVacom vaccine based on mRNA technology and BioNTech and Modernino is in the final stages of clinical trials involving 40,000 volunteers. At this stage, one part of them received the vaccine and the other part received a placebo, and then monitored which of these two groups had contracted the corona in their daily lives and their disease process.
According to CureVac, 13 different coronavirus variants have been found in their volunteers so far. Only one case fell on the original variant spread from China, which shows that the mutation has completely occupied the primacy position.
What is certain is that the CureVacom vaccine will not be approved by the European Medicines Agency in June. The question is whether it will be approved. “The final efficiency may be different,” said Franz-Werner Haas, the company’s chief executive, who admitted that he expects better interim results.
German Health Minister Jens Spahn also expects better results, and he is now talking about “very disappointed.”
No wonder-by the end of June, Germany had already counted on 1.4 million doses of CureVac. The EU has provided a total of 405 million doses of this vaccine in advance, and it seems that mass production will never begin.
“Manager” magazine, which deals with themes of the business world, wrote that CureVac “betting on the opportunities of this century.” According to the magazine, the billionaire and investor Dietmar Hope delegated the matter to the wrong management.
The situation in Mainz is different. BioNTech is headquartered in Mainz, and the company has developed the first Western-approved corona vaccine in cooperation with Pfizer. The value of BioNTech skyrocketed, and the fortune of leading scientist and company founder Ugur Sahin is estimated at $8.6 billion.